Company intelligence / Profile preview

e-Bio

Ownership: Private
Development stage: Preclinical

Overview

e-Bio is a clinical-stage medical device company developing an innovative, non-pharmacological solution to stop preterm labor using electric inhibition technology. The company has received FDA Investigational Device Exemption (IDE) and is currently conducting human trials, supported by encouraging early results and a grant from March of Dimes[4].

Therapeutic areas: Women's Health
Modalities: Medical device (electric inhibition technology)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Anti-17 MLNPs

Pre-clinical

Indications: Alzheimer's disease

Partnerships

March of Dimes (grant support for clinical trial)[4]

Beyond the preview

Go deeper on e-Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on e-Bio.

Explore the full profile